Global Next-Generation Sequencing Services Market

Next-Generation Sequencing Services Market Size, Share, Growth Analysis, By Service type(Human Genome Sequencing, Single Cell Sequencing, Microbial Genome-based Sequencing, Gene Regulation Services), By Workflow(Pre-sequencing, Sequencing, Data Analysis), By Technology(Sequencing By Synthesis (SBS), Ion Semiconductor Sequencing (IOS), Single-molecule Real-time Sequencing (SMRT), Nanopore Sequencing), By Application(Diagnostics, Drug Discovery, Biomarker Discovery, Agriculture & Animal Research), By End User(Universities & Other Research Entities, Hospitals & Clinics, Pharma & Biotech Entities, others), By Region - Industry Forecast 2024-2031


Report ID: SQSG35A2092 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 152 | Figures: 78

Next-Generation Sequencing Services Market Insights

Global Next-Generation Sequencing Services Market size was valued at USD 4.16 billion in 2019 and is poised to grow from USD 7.31 billion in 2023 to USD 24.5 billion by 2031, growing at a CAGR of 22.56% in the forecast period (2024-2031).

Next-generation sequencing (NGS), also referred to as massively parallel sequencing (MPS) is used to refer to a DNA sequencing technology that has greatly benefited the disciplines of biotechnology, medical diagnosis, forensic biology, biological systematics, and virology. Clinical research, basic research, and applied science have all transformed as a result of the development of NGS. With the next-generation sequencing technology, a full human genome can be sequenced in a lot less time than with the older Sanger sequencing technology. The order of nucleotides throughout the genome can be determined quickly, scalable, and with a very high throughput. DNA pre-sequencing is one of the most crucial steps in the entire sequencing methodology since it includes preparing the material for the subsequent sequencing reaction. NGS is increasingly being used in clinical laboratory analysis, testing, and illness diagnosis across the globe. The drug discovery process in pharmacogenomic is frequently accelerated using next-generation sequencing (NGS).

The identification of biomarkers for early diagnosis and individualised treatments is made possible by next-generation sequencing, which has had a substantial impact on the shift from the traditional medical model of diagnosis to a precision medicine model. Although Next Generation Sequencing is a relatively new technology, it has already made major contributions to molecular biology, genetics, and the disciplines of personalised medicine, hereditary illnesses, and clinical diagnostics.

US Next-Generation Sequencing Services Market is poised to grow at a sustainable CAGR for the next forecast year.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Next-Generation Sequencing Services Market size was valued at USD 4.16 billion in 2019 and is poised to grow from USD 7.31 billion in 2023 to USD 24.5 billion by 2031, growing at a CAGR of 22.56% in the forecast period (2024-2031).

Global Next-Generation Sequencing Services Market is highly fragmented due to presence of many prominent players. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. Key player includes Agilent Technologies, Inc., BGI Group, F. Hoffmann-La Roche AG, Illumina Inc and Precigen Inc. Prominent Players are spending more on R&D to create the technologically superior system that provides them an edge over rivals. 'Eurofins scientific, ', 'Illumina, Inc.', 'Thermo Fisher Scientific, Inc.', 'Pacific Biosciences of California, Inc.', 'BGI Group', 'Qiagen N.V.', 'Oxford Nanopore Technologies, Ltd.', 'F. Hoffmann-La Roche Ltd.', 'Becton, Dickinson and Company', 'GENEWIZ, Inc.', 'Perkinelmer Inc.', 'Macrogen, Inc.', 'Agilent Technologies, Inc.', 'GATC Biotech AG', 'Partek Incorporated', 'PierianDx', 'NantOmics, LLC', '10x Genomics, Inc.', 'GenScript Biotech Corporation', 'DNASTAR, Inc. '

The market demand is being driven by advancements in clinical diagnosis. Forensics, reproductive health, individualised medicine, biomarkers, and diagnostics are just a few of the uses for next-generation sequencing. Due to the analytical accuracy, high throughput, and cost-effectiveness of next-generation sequencing (NGS), it has become the industry standard for clinical laboratories to use NGS for diagnosing genetic illnesses. So, a feasible alternative to treating rare disorders is genomic sequencing-based diagnosis.

Clonal amplification would not be required with a new sequencing technology that does not employ the polymerase chain reaction (PCR) and instead uses single molecule sequencing and single real-time sequencing, thereby avoiding PCR-related mistakes. Third-generation sequencing equipment were created as a result of these desires following the emergence of next-generation technology. These are based on single-molecule sequencing and are capable of producing longer read lengths with less complex preparatory procedures. Examples include the SMRT (Single-Molecule Real-Time) DNA Sequencing Method, the FRET Sequencing Platform, and Nanopore Sequencing. Single molecule real-time sequencing (SMRT) is a platform that can produce read lengths of about a thousand bases using single molecule real-time sequencing. The FRET Sequencing platform makes use of a DNA polymerase modified with a quantum dot, base fluorescence tagging technology, and DNA template molecules mounted on a solid surface.

North America region held the largest Global next-generation sequencing services market share and accounted for approximately 45% revenue share during 2021 on account of features such a strong regulatory framework for the approval and use of genetic tests, an established informatics network, and the presence of market leaders in the area. Additionally, it is projected that the expanding number of FDA-approved genetic tests in the U.S. will fuel the local market throughout the course of the forecast period. Pharmaceutical businesses in North America are prioritising the introduction of comprehensive genome sequencing efforts, the establishment of reimbursement and regulatory guidelines for NGS-based diagnostic tools, and the creation of precision and personalised medicines.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Next-Generation Sequencing Services Market

Report ID: SQSG35A2092

$5,300
BUY NOW GET FREE SAMPLE